Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with aggressive large B-cell lymphoma (like diffuse large B-cell lymphoma or transformed follicular lymphoma).
- You are eligible to receive approved CAR T-cells as your 2nd, 3rd, or 4th line of treatment.
- You have a high total metabolic tumor volume on a PET scan just before CAR T-cell treatment.
- You have good kidney function (creatinine clearance above 45 mL/min) and normal liver tests.
- You are not pregnant, not breastfeeding, and use effective contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests a combination of three drugs (golcadomide, poseltinib, and rituximab) for people with a type of lymphoma that has returned or not responded to previous treatment. The goal is to see if this combination is safe and effective for those who cannot have a stem cell transplant.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
Hear when a new Refractory Primary Mediastinal Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.